Emily Liffick

559 total citations
17 papers, 422 citations indexed

About

Emily Liffick is a scholar working on Psychiatry and Mental health, Philosophy and Experimental and Cognitive Psychology. According to data from OpenAlex, Emily Liffick has authored 17 papers receiving a total of 422 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 4 papers in Philosophy and 3 papers in Experimental and Cognitive Psychology. Recurrent topics in Emily Liffick's work include Schizophrenia research and treatment (6 papers), Mental Health and Psychiatry (4 papers) and Migraine and Headache Studies (3 papers). Emily Liffick is often cited by papers focused on Schizophrenia research and treatment (6 papers), Mental Health and Psychiatry (4 papers) and Migraine and Headache Studies (3 papers). Emily Liffick collaborates with scholars based in United States and Italy. Emily Liffick's co-authors include Alan Breier, Jenifer L. Vohs, Michael Francis, Nicole F. Mehdiyoun, Tom A. Hummer, Erin Doty, Kelly D. Buck, Bethany L. Leonhardt, Paul H. Lysaker and Jay A. Hamm and has published in prestigious journals such as Neurology, Biological Psychiatry and Schizophrenia Bulletin.

In The Last Decade

Emily Liffick

16 papers receiving 410 citations

Peers

Countries citing papers authored by Emily Liffick

Since Specialization

Citations

This map shows the geographic impact of Emily Liffick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Liffick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Liffick more than expected).

Fields of papers citing papers by Emily Liffick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Liffick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Liffick. The network helps show where Emily Liffick may publish in the future.

Co-authorship network of co-authors of Emily Liffick

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Liffick. A scholar is included among the top collaborators of Emily Liffick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Liffick. Emily Liffick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia 2020 ·Brain Imaging and Behavior ·Michael Francis, Tom A. Hummer, Emily Liffick, Jenifer L. Vohs, (unknown), (unknown), Ziyi Yang, Richard J. Kovacs, (unknown), Alan Breier	14
2	S32. ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS POTENTIAL THERAPEUTICS FOR SCHIZOPHRENIA? 2020 ·Schizophrenia Bulletin ·Alan Breier, Emily Liffick, Tom A. Hummer, (unknown), Nicole F. Mehdiyoun, Ziyi Yang, Andrew J. Saykin, Brenna C. McDonald, Michael Francis	2
3	Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat 2019 ·The Journal of Clinical Pharmacology ·Brian A. Willis, Scott W. Andersen, (unknown), Douglas E. James, Emily Liffick, Kathleen M. Hillgren, Yingying Guo, Scott A. Monk	7
4	Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN 2019 ·Cephalalgia ·John H. Krege, Paul Rizzoli, Emily Liffick, Erin Doty, Sherie A. Dowsett, Jianing Wang, Andrew Buchanan	51
5	Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine (P1.10-009) 2019 ·Neurology ·John H. Krege, Emily Liffick, Erin Doty, Sherie A. Dowsett, (unknown), Andrew Buchanan	2
6	Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study 2019 ·The Journal of Clinical Pharmacology ·Darren Wilbraham, Paul H. Berg, Max Tsai, Emily Liffick, Li Shen Loo, Erin Doty, Edward M. Sellers	22
7	Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders 2018 ·Schizophrenia Research ·Alan Breier, Emily Liffick, Tom A. Hummer, Jenifer L. Vohs, Ziyi Yang, Nicole F. Mehdiyoun, (unknown), (unknown), Ying Zhang, Michael Francis	78
8	Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study 2018 ·Brain Imaging and Behavior ·Michael Francis, Tom A. Hummer, Jenifer L. Vohs, (unknown), (unknown), (unknown), Teresa C. Kulig, Miji Um, Ziyi Yang, (unknown), Emily Liffick, Ying Zhang, Alan Breier	28
9	402. The Effects of 12-month, Double-Blind N-Acetyl Cysteine Treatment on Symptoms and Brain Structures in Early Phase Psychosis 2017 ·Biological Psychiatry ·Alan Breier, Tom A. Hummer, Emily Liffick, Alexander J. Radnovich, (unknown), (unknown), Spencer Lourens, (unknown), Teresa C. Kulig, Michael Francis	1
10	Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814). 2017 ·PubMed ·John R. Sims, Katherine J. Selzler, AnnCatherine M. Downing, Brian A. Willis, Christopher D. Aluise, J Zimmer, Sonja M. Bragg, Scott W. Andersen, (unknown), Emily Liffick, Jennifer R. Eads, Alette M. Wessels, Scott A. Monk, Jennifer Schumi, (unknown)	18
11	Characterization of white matter abnormalities in early‐stage schizophrenia 2016 ·Early Intervention in Psychiatry ·Tom A. Hummer, Michael Francis, Jenifer L. Vohs, Emily Liffick, Nicole F. Mehdiyoun, Alan Breier	15
12	Utilization and Cost of Health Care Services During the First Episode of Psychosis 2016 ·Psychiatric Services ·Emily Liffick, Nicole F. Mehdiyoun, Jenifer L. Vohs, Michael Francis, Alan Breier	10
13	Metacognitive Capacity as a Predictor of Insight in First-Episode Psychosis 2015 ·The Journal of Nervous and Mental Disease ·Jenifer L. Vohs, Paul H. Lysaker, Emily Liffick, Michael Francis, Bethany L. Leonhardt, Alison V. James, Kelly D. Buck, Jay A. Hamm, Kyle S. Minor, (unknown), Alan Breier	32
14	Functional neuroanatomical correlates of episodic memory impairment in early phase psychosis 2015 ·Brain Imaging and Behavior ·Michael Francis, Tom A. Hummer, Jenifer L. Vohs, (unknown), Emily Liffick, Nicole F. Mehdiyoun, Alexander J. Radnovich, Brenna C. McDonald, Andrew J. Saykin, Alan Breier	38
15	Metacognition, social cognition, and symptoms in patients with first episode and prolonged psychoses 2014 ·Schizophrenia Research ·Jenifer L. Vohs, Paul H. Lysaker, Michael Francis, Jay A. Hamm, Kelly D. Buck, Kyle Olesek, (unknown), Giancarlo Dimaggio, Bethany L. Leonhardt, Emily Liffick, Nicole F. Mehdiyoun, Alan Breier	102
16	Pharmacotherapy of First-Episode Schizophrenia 2010 ·Emily Liffick, Alan Breier	1
17	Children of Psychiatrists 2005 ·Psychiatric News ·Emily Liffick	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact